NasdaqCM:RMTI - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2025	103	1	N/A	N/A	2
12/31/2024	92	-4	N/A	N/A	2
3/31/2024	87	-9	-8	-8	N/A
12/31/2023	84	-9	-10	-9	N/A
9/30/2023	81	-9	-10	-10	N/A
6/30/2023	76	-12	-8	-7	N/A
3/31/2023	76	-13	-11	-11	N/A
12/31/2022	73	-19	-17	-17	N/A
9/30/2022	69	-25	-26	-26	N/A
6/30/2022	66	-29	-32	-32	N/A
3/31/2022	63	-32	-31	-31	N/A
12/31/2021	62	-33	-34	-34	N/A
9/30/2021	62	-32	-34	-33	N/A
6/30/2021	61	-32	-32	-31	N/A
3/31/2021	62	-31	-36	-36	N/A
12/31/2020	62	-31	-31	-30	N/A
9/30/2020	63	-30	-27	-26	N/A
6/30/2020	63	-30	-28	-28	N/A
3/31/2020	62	-33	-30	-28	N/A
12/31/2019	61	-34	-29	-27	N/A
9/30/2019	63	-36	-29	-28	N/A
6/30/2019	64	-33	-28	-26	N/A
3/31/2019	64	-35	-22	-21	N/A
12/31/2018	63	-32	-21	-20	N/A
9/30/2018	61	-32	-21	-19	N/A
6/30/2018	59	-32	-20	-19	N/A
3/31/2018	58	-27	-22	-21	N/A
12/31/2017	57	-26	N/A	-21	N/A
9/30/2017	56	-22	N/A	-16	N/A
6/30/2017	54	-21	N/A	-18	N/A
3/31/2017	54	-20	N/A	-16	N/A
12/31/2016	53	-20	N/A	-12	N/A
9/30/2016	54	-21	N/A	-16	N/A
6/30/2016	56	-18	N/A	-13	N/A
3/31/2016	55	-16	N/A	-14	N/A
12/31/2015	55	-14	N/A	-13	N/A
9/30/2015	56	-15	N/A	4	N/A
6/30/2015	55	-17	N/A	8	N/A
3/31/2015	55	-17	N/A	11	N/A
12/31/2014	54	-21	N/A	4	N/A
9/30/2014	54	-23	N/A	-21	N/A
6/30/2014	53	-33	N/A	-31	N/A
3/31/2014	53	-41	N/A	-50	N/A
12/31/2013	52	-49	N/A	-51	N/A
9/30/2013	51	-54	N/A	-50	N/A
6/30/2013	51	-59	N/A	-49	N/A

アナリストによる今後の成長予測

収入対貯蓄率: RMTI今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: RMTI今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: RMTI今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: RMTIの収益 ( 9.8% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: RMTIの収益 ( 9.8% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: RMTIの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Rockwell Medical 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Consensus EPS estimates fall by 35%, revenue upgraded

Rockwell Medical, Inc. Revises Earnings Guidance for the Year 2024

Consensus EPS estimates upgraded to US$0.10 loss, revenue downgraded

Rockwell Medical, Inc. Provides Earnings Guidance for Fourth Quarter and Full-Year 2023

Rockwell Medical, Inc. Provides Financial Guidance for the Year 2023

Forecast to breakeven in 2025

Recent updates

New major risk - Financial position

Rockwell Medical, Inc. Promotes Tim Chole to Chief Commercial Officer

Consensus EPS estimates fall by 35%, revenue upgraded

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Rockwell Medical, Inc. Revises Earnings Guidance for the Year 2024

Does Rockwell Medical (NASDAQ:RMTI) Have A Healthy Balance Sheet?

Rockwell Medical, Inc. to Report Q1, 2024 Results on May 14, 2024

Rockwell Medical, Inc., Annual General Meeting, May 21, 2024

Consensus EPS estimates upgraded to US$0.10 loss, revenue downgraded

New minor risk - Share price stability

Full year 2023 earnings: EPS exceeds analyst expectations

Rockwell Medical, Inc. to Report Q4, 2023 Results on Mar 21, 2024

Is Rockwell Medical (NASDAQ:RMTI) A Risky Investment?

Rockwell Medical, Inc. Provides Earnings Guidance for Fourth Quarter and Full-Year 2023

Rockwell Medical, Inc. (NASDAQ:RMTI) Doing What It Can To Lift Shares

New major risk - Financial position

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rockwell Medical, Inc. Provides Financial Guidance for the Year 2023

Rockwell Medical, Inc. Appoints Jesse Neri as Senior Vice President, Finance

Rockwell Medical, Inc. Appoints Joan Lau, Ph.D. to the Company's Board of Directors

Rockwell Medical, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Is Rockwell Medical (NASDAQ:RMTI) Using Too Much Debt?

Forecast to breakeven in 2025

Rockwell Medical, Inc. Announces Resignation of as Senior Vice President, Finance and Chief Accounting Officer

Consensus EPS estimates fall by 23%

Rockwell Medical, Inc. Revises Financial Guidance for the Year 2023

Second quarter 2023 earnings: EPS misses analyst expectations

Consensus estimates of losses per share improve by 15%

Rockwell Medical, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Rockwell Medical, Inc. (NasdaqCM:RMTI) agreed to acquire Substantially All Assets of Evoqua Water Technologies LLC for $16 million.

New major risk - Share price stability

Is Rockwell Medical (NASDAQ:RMTI) Weighed On By Its Debt Load?

Consensus estimates of losses per share improve by 13%

Rockwell Medical, Inc. Provides Revenue Guidance for Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Rockwell Medical, Inc. to Report Q4, 2022 Results on Mar 30, 2023

Price target decreased to US$5.00

Rockwell Medical, Inc. Provides Earnings Guidance for the Full Year 2022

Is There Now An Opportunity In Rockwell Medical, Inc. (NASDAQ:RMTI)?

Rockwell Medical, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Rockwell Medical, Inc. Names Heather Hunter as SVP, Chief Corporate Affairs Officer

An Intrinsic Calculation For Rockwell Medical, Inc. (NASDAQ:RMTI) Suggests It's 46% Undervalued

Consensus estimates of losses per share improve by 24%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Rockwell Medical Q2 Earnings Preview

Rockwell Medical, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Price target decreased to US$19.00

Rockwell Medical, Inc. Provides Clinical Update

Rockwell Medical, Inc. announced that it has received $14.9 million in funding

Rockwell Medical Regains Compliance with Nasdaq Listing Requirements

Rockwell Medical, Inc. Submits Supplemental Data to FDA for IND Application for Phase 2 FPC Home Infusion Trial

Rockwell Medical, Inc. to Report Q1, 2022 Results on May 16, 2022

Rockwell Medical, Inc. Announces Completion of Patient Enrollment Ahead of Schedule in Pivotal Phase 3 Clinical Trial of Triferic(R) in China

Rockwell Medical, Inc. announced delayed annual 10-K filing

Rockwell Medical: Triferic Remains Key Despite Sluggish Growth Profile

Forecast to breakeven in 2023

Price target decreased to US$4.00

Rockwell Medical Receives Important Feedback from FDA on Its IND Application for Phase 2 Trial of Ferric Pyrophosphate Citrate in Home Infusion

Third quarter 2021 earnings released: US$0.081 loss per share (vs US$0.10 loss in 3Q 2020)

Rockwell Medical: Down But By No Means Out

Second quarter 2021 earnings released: US$0.09 loss per share (vs US$0.099 loss in 2Q 2020)

Rockwell Medical Receives Written Notice from the Nasdaq Stock Market

Rockwell Medical pops 6% on licensing deal for Triferic AVNU in Turkey

First quarter 2021 earnings released: US$0.083 loss per share (vs US$0.12 loss in 1Q 2020)

Rockwell Medical, Inc. Announces Marketing Approval of Triferic® AVNU™ in Canada

Rockwell Medical, Inc. to Report Q4, 2020 Results on Mar 31, 2021

Health Check: How Prudently Does Rockwell Medical (NASDAQ:RMTI) Use Debt?

Rockwell Medical Announces U.S. Availability of Triferic AVNU for Replacement of Iron and Maintenance of Hemoglobin in Patients on Hemodialysis